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Osteoarthritis is characterized by the loss of articular cartilage, bone remodeling, pain and 
disability. No pharmacological intervention can currently halt progression of osteoarthritis. Here 
we show that blocking receptor tyrosine kinase like orphan receptor 2 (ROR2) improves 
cartilage integrity and pain in osteoarthritis models by inhibiting yes associated protein (YAP) 
signaling.  ROR2 was upregulated in cartilage in response to inflammatory cytokines and 
mechanical stress. The main ligand for ROR2, WNT5A, and the targets YAP and connective 
tissue growth factor (CTGF) were upregulated in osteoarthritis in humans. In vitro, ROR2 
overexpression inhibited chondrocytic differentiation. Conversely, ROR2 blockade triggered 
chondrogenic differentiation of C3H10T½ cells and suppressed the expression of the cartilage 
degrading enzymes a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS)-4 and -5. The chondrogenic effect of ROR2 blockade in cartilage was independent 
of WNT signaling and was mediated by downregulation of YAP signaling. ROR2 signaling 
induced G-protein and Rho-dependent nuclear accumulation of YAP and YAP inhibition was 
required but not sufficient for ROR2 blockade-induced chondrogenesis. ROR2 silencing 
protected mice from instability-induced osteoarthritis with improved structural outcomes, 
sustained pain relief, and without apparent side effects or organ toxicity. Finally, ROR2 silencing 
in human articular chondrocytes transplanted in nude mice led to the formation of cartilage 
organoids with more and better-differentiated extracellular matrix, suggesting that the anabolic 
effect of ROR2 blockade is conserved in humans. Thus, ROR2 blockade is efficacious and well-




Osteoarthritis is a joint disease characterized by breakdown of the articular cartilage (the tissue 
that covers the ends of the long bones allowing frictionless joint motion) and bone changes 
including thickening of the bone supporting the cartilage and excessive bone formation at the 
margins of the joint (osteophytes). Osteoarthritis affects up to a third of the population over the 
age of 45 (1), is the main cause of chronic disability worldwide, and costs between 1 and 2% of 
the gross domestic product in westernized countries (2–5). Osteoarthritis is caused by 
pathological chronic mechanical injury due to excessive body weight, joint malalignment or joint 
instability that may be a consequence of lesions to ligaments and menisci. Low-degree 
inflammation is sometimes present in osteoarthritic joints as a result of tissue damage but is not a 
major driver of disease progression.  
Chondrocytes, the only type of cell present in the cartilage, produce a glycosaminoglycan 
(GAG)-rich extracellular matrix (ECM), which confers the tissue its biomechanical properties. In 
resting conditions, the ECM has an extremely low turnover (6). After injury, however, 
homeostatic mechanisms are deployed, which include upregulation of the cartilage transcription 
factor SRY-box transcription factor 9 (SOX9) and of its transcriptional targets COL2A1 and 
ACAN, encoding for the major ECM components collagen type II and aggrecan.  Small cartilage 
lesions can heal, albeit often incompletely (7, 8), however when the injury is too severe and/or 
persists, the homeostatic response becomes insufficient. Further ECM remodeling takes place 
through coordinated matrix synthesis and degradation, the latter driven by the activation of 
matrix metalloproteinases and aggrecanases (9–11).  
Genetic studies in humans and mice have linked mutations leading to excessive activation of 
canonical WNT signaling to osteoarthritis development (12–17). WNTs are a family of 19 
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pleiotropic morphogens that, after binding to Frizzled (FZD) receptors, can signal through 
multiple pathways classified as β-catenin dependent or independent. In the β-catenin-dependent 
canonical pathway, WNT ligands engage with FZDs and the co-receptors lipoprotein-related 
protein receptors (LRP)-5 or LRP-6. β-catenin accumulates in the cytoplasm and translocates to 
the nucleus, binds to T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factors, 
and activates the transcription of cell-specific target genes. WNT/β-catenin-independent 
pathways are characterized by dimerization of FZDs with different co-receptors. One of these, 
the planar cell polarity (PCP) pathway, requires the co-receptor ROR2 to be activated (18, 19), 
leading to the phosphorylation of the intracellular molecule Van Gogh-like 2 (VANGL2) (18) 
and ultimately the suppression of canonical WNT signaling. ROR1, a closely related receptor, 
modulates other signaling pathways including the Hippo pathway. The Hippo pathway regulates 
cell growth and organ size and differentiation. Stimuli (such as mechanical) activating the Hippo 
pathway result in the inhibition of the YAP/tafazzin (TAZ) transcriptional co-activators through 
direct phosphorylation, ubiquitination and degradation. Inhibition of the Hippo pathway results 
in accumulation of YAP/TAZ, their translocation to the nucleus, where they bind to TEA domain 
transcription factor (TEAD) and promote target gene transcription (20). Targets of the ROR-
YAP cascade include WNT5A and CTGF (21). 
Excessive activation of WNT/β catenin signaling promotes a form of terminal differentiation 
called chondrocyte hypertrophy (22). During skeletal development, chondrocyte hypertrophy 
precedes cartilage calcification and ultimately its replacement by bone. Under physiological 
conditions articular chondrocytes are resistant to hypertrophy. During osteoarthritis however, 




During embryonic development, Ror2 is expressed mainly in the cartilage structures that will 
persist throughout life including the anterior portion of the ribs and prospective articular 
cartilage, but also in the growth plate and other organs such as the dermis and the embryonic 
telencephalon (25, 26). Loss of ROR2 during development results in shorter long bones and 
delayed cartilage calcification, hypertrophy and endochondral bone formation (26). In humans, 
loss of ROR2 results in recessive Robinow syndrome, a form of dwarfism that is closely 
phenocopied by ROR2 loss in mice (27, 28). Despite the developmental phenotype of skeletal 
dysplasia, however, subjects with Robinow syndrome do not display postnatal phenotypes. This 
suggests that, in physiological conditions, the postnatal functions of ROR2 are compensated. 
Because of the exquisite expression of ROR2 in the articular cartilage and its effects pre-
eminently on cartilage development, in this manuscript we tested whether ROR2 blockade 
affects cartilage homeostasis during experimental osteoarthritis and cartilage formation. 
Results 
ROR2 signaling is upregulated in osteoarthritis 
ROR2 was detected in the most superficial layer of the articular cartilage in mouse embryos at 
stage 18.5 days post coitum (Fig. 1A). This expression pattern is similar to that described by in 
situ hybridization (26) and therefore validated our antibody. Postnatally, one week after inducing 
osteoarthritis by joint destabilization, ROR2 became detectable in the upper third of the articular 
cartilage (Fig. 1B). Using expression microarrays in patient samples (29), ROR2 was detected in 
osteoarthritic cartilage as well as in cartilage of patients without osteoarthritis, whereas the main 
ROR2 ligand, WNT5A (30–33),was more highly expressed in osteoarthritic cartilage and 
correlated with the expression of the ROR targets YAP and CTGF (21), and inversely with SOX9 
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[Fig. 1C and fig. S1, A and D; (29)]. A principal component analysis showed that such 
parameters were sufficient to separate healthy from osteoarthritic cartilage samples and, whereas 
WNT5A contributed mostly to principal component one (explaining 55.5% of variance), ROR2 
contributed mostly to principal component 2 (explaining an additional 18%; fig. S1, A to C). At 
protein level, ROR2 was detected in the superficial layer of osteoarthritic cartilage by 
immunostaining (Fig. 1D) and confirmed by western blotting in cartilage and synovial 
membrane (Fig. 1E) in human samples. 
 
To better define the temporal dynamics of ROR2 expression in osteoarthritis, we mined 
microarray data deposited in the GEO database at NCBI [GEO accession GSE41342; (34)]. This 
analysis revealed an early peak of Ror2 upregulation within the first 2-4 weeks after joint 
destabilization, possibly associated with post-surgical inflammation (Fig. 1F). The expression 
patterns of Wnt5a, Yap and Ctgf were similar to that of Ror2 (Fig. 1F). In keeping with 
inflammation triggering ROR2 expression, the analysis of a publicly available dataset [GEO 
accession GSE75181; (35)] revealed that exposure of primary human articular chondrocytes to 
interleukin 1β(IL-1β) resulted in upregulation of ROR2 and WNT5A (Fig. 1G). In accordance 
with the role of mechanical injury in triggering osteoarthritis, explanting murine femoral head 
articular cartilage from the subchondral bone, a model of mechanical injury, led to short-term 
upregulation of ROR2 (Fig. 1, H and I and fig. S2). These data suggest that the WNT5A/ROR2 
pathway is activated in osteoarthritis. 
ROR2/WNT5A expression correlates with chondrocytic differentiation 
To investigate the role of ROR2 in chondrocyte biology, we first correlated the expression of 
WNT5A and ROR2 in human chondrocytes and synovial membrane-derived mesenchymal stem 
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cells (SM-MSCs) at different stages of differentiation. Serial passaging results in progressive 
loss of chondrocyte phenotypic markers and in the capacity of these cells to form cartilage in 
vivo (36). The expression of ROR2 progressively decreased from passage 0 to  passage 8 [fig. 
S3A and B (37)]. Although ROR2 expression did not change with transforming growth factor β 
(TGF-β)-induced chondrocytic differentiation of SM-MSCs (38), expression of WNT5A 
increased sharply in differentiating conditions (fig. S3C and D). 
ROR2 gain of function inhibits chondrocytic differentiation 
To investigate if the amount of ROR2 influences the degree of chondrocytic differentiation we 
performed gain of function studies using a mesenchymal cell line. We tested whether ROR2 
overexpression (fig. S4A) modulated the capacity of C3H10T½ cells to differentiate in response 
to bone morphogenetic protein 2 [BMP2; (39)]. As expected, BMP2 induced rapid chondrocytic 
differentiation of C3H10T½ cells, as assessed by Alcian blue staining. Unexpectedly, ROR2 
overexpression inhibited chondrogenic differentiation of C3H10T½ cells in response to BMP2 
(Fig. 2A and B). Even in the absence of exogenous BMP2, ROR2 overexpression reduced the 
expression of the chondrocytic differentiation markers Col2a1 and Acan (Fig 2C and D). The 
bone and fibroblast marker collagen type I (Col1a1) and the cartilage hypertrophy marker 
collagen type X (ColX) were not significantly regulated (Fig. 2E and F). The cartilage stem cell 
marker Sox2, normally expressed in the superficial zone cells did not change significantly. ROR2 
overexpression upregulated the proliferation marker proliferating cell nuclear antigen (PCNA) 
(Fig. 2G and H).  
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ROR2 loss of function supports chondrocytic differentiation 
We designed small interfering RNA (siRNA) that silenced ROR2 expression by about 73% at 
protein level in vitro (fig. S4B). A short hairpin RNA (shRNA)-lentivirus downregulated ROR2 
mRNA by 92% and protein by 56% (Fig. 3A and fig. S4C). The expression of Ror1 did not 
change, confirming the specificity of RNA interference and that there was no compensation (Fig. 
3A). Using either the siRNA or shRNA-lentivirus, ROR2 silencing induced chondrocytic 
differentiation of C3H10T½ cells, even without BMP2, as assessed by Alcian blue staining (Fig. 
3B and C), and Aggrecan mRNA expression (Fig. 3D). ROR2 silencing inhibited the expression 
of Col2A1 and of the key cartilage degrading enzymes ADAMTS-4 (9) and ADAMTS-5 (10, 11) 
(Fig. 3E and F).  
ROR2 silencing in vivo improves symptoms and structural features of osteoarthritis 
The anabolic effect of ROR2 blockade and the suppression of key catabolic enzymes prompted 
us to test whether ROR2 loss of function may be beneficial in osteoarthritis. In vivo, 
chondrocytes are difficult to target with traditional therapeutics and macromolecules because the 
articular cartilage is avascular and chondrocytes are encased in a dense, strongly negatively 
charged ECM (40, 41). We used siRNA coupled with atelocollagen as it was previously shown 
to efficiently target murine cartilage (42, 43). In time course and dose-response experiments we 
established that intra-articular injection of 7 μL of 20 µM ROR2-siRNA conjugated to 0.5% 
atelocollagen (ROR2i) achieved ~50% reduction of ROR2 protein expression compared to 
scrambled siRNA for as long as 5 days (Fig. 4A and fig. S5). Importantly, this silencing 
efficiency was sufficient to downregulate the ROR target CTGF (21) by ~60% (Fig. 4B and C).  
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To assess the efficacy of ROR2i in a model of instability induced osteoarthritis, we 
subjected skeletally mature mice to menisco-ligament injury [MLI; (44–46)]. Two weeks after 
surgery, when cartilage lesions are established (47), the mice received bilateral intra-articular 
injections of either ROR2i or scrambled siRNA (control) every 5 days. After 5 weeks of 
treatment, half of the mice receiving ROR2i were switched to receive scrambled siRNA 
(crossover group, Fig. 4D). Starting 7 weeks after surgery, the control group developed pain on 
weight bearing (incapacitance) as measured by the percentage of body weight loaded on each 
limb (Fig. 4E). Strikingly, the mice receiving ROR2i did not develop pain. The crossover group 
remained pain-free for additional 3 weeks after treatment was swapped before developing pain, 
without ever reaching the same pain threshold as the control group (Fig. 4E and F). Twelve 
weeks after surgery all mice were euthanized. The area under the curve (AUC) for all treatments 
between week 5 and 12 was higher in the ROR2i group compared to control, whereas the 
crossover group had an intermediate outcome (Fig. 4G). To validate that the reduction of body 
weight loaded on the operated limb was due to pain and not due to other factors such as reduced 
range of movement or muscle weakness, we administered buprenorphine, an opioid analgesic, or 
saline to mice from the control group which had high incapacitance 12 weeks after surgery. After 
1 hour, incapacitance normalized in the group that received buprenorphine but not in the mice 
that received saline (Fig. 4H), thereby confirming that incapacitance, in this model, measures 
pain at weight bearing. 
ROR2i reduced the degree of structural damage to cartilage as assessed by Osteoarthritis 
Research Society International (OARSI) score (Fig. 4I and J) and histomorphometric 
quantification of safranin O staining (Fig. 4K). The crossover group, again, had an intermediate 
outcome. As expected, bone density increased in the destabilized knee compared to the 
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contralateral, sham-operated, or non-operated knees, however there were no differences between 
treatments as assessed by micro computed tomography (μCT) (fig. S6A) or histomorphometry 
(fig. S6B). No differences were detected in synovial lining thickness, osteophyte perimeter or 
area (fig. S6C to E). Importantly, no overt toxicity or differences in body weight between groups 
were observed throughout the course of treatment (Fig. 4L). ROR2i did not alter liver, kidney, 
muscle or bone parameters (table S1). Similar results, both in terms of pain and structural 
outcomes, were obtained in an independent experiment when ROR2i was started four weeks 
after surgery (fig. S7). 
ROR2 silencing supports formation of human cartilage organoids in vivo 
One problem with translating data from murine models to patients is the degree of conservation 
of molecular pathways across the species. To test whether ROR2 blockade induces cartilage 
formation in vivo in human chondrocytes we used an established adoptive model (48–50). 
Human articular chondrocytes transduced with ROR2-shRNA lentivirus and implanted 
subcutaneously in nude mice formed cartilage organoids that were more differentiated than those 
obtained from chondrocytes transduced with control shRNA (Fig. 5). This confirms that ROR2 
blockade is sufficient to support cartilage differentiation in human chondrocytes obtained from 
joints with end-stage osteoarthritis in vivo in mice.  
Mechanism of action of ROR2 blockade  
In keeping with previous literature, we found that overexpression of ROR2 in HEK293 cells 
inhibited the capacity of WNT3A to activate canonical WNT signaling as assessed using the 
SUPER8TOPFlash reporter assay (51, 52). As expected, co-stimulation with WNT5A enhanced 
the capacity of ROR2 to inhibit WNT3A-induced activation of WNT signaling (Fig. 6A). 
 
11 
Inhibition of the WNT/β-catenin branch induced by ROR2 overexpression was confirmed in the 
mesenchymal cell line C3H10T½ (Fig. 6B). In contrast to HEK293 cells, in C3H10T½ cells co-
stimulation with WNT5A had no additional effect. This discrepancy may be due to high Ror2 
expression in C3H10T1/2 cells whereas ROR2 mRNA was undetectable in HEK293 cells (fig. 
S8). Therefore, activation of ROR2 signaling in C3H10T½ by endogenous WNT5A or other 
WNTs present in the cell culture medium may be causing the ceiling effect under these 
experimental conditions, although other differences between the two cell lines in terms of their 
ROR2 signaling machinery cannot be excluded.  ROR2 overexpression did not inhibit the 
capacity of the glycogen synthase kinase 3β  (GSK3-β) inhibitor 6-bromoindirubin-3'-oxime 
(BIO) to activate WNT signaling, thereby suggesting that the inhibitory effect is upstream of 
GSK3-β (53) (Fig. 6C).  Unexpectedly, in C3H10T½ cells ROR2 silencing did not result in 
dysregulation and increased activation of canonical WNT signaling by WNT3A (Fig. 6D). For 
this reason, and because activation of canonical WNT signaling inhibits chondrogenesis (50, 54, 
55), de-repression of canonical WNT signaling was unlikely to be responsible for the 
chondrogenic effect of ROR2 inhibition. The closely related receptor ROR1 was recently shown 
to regulate the hippo pathway including YAP and its downstream targets Ctgf and Wnt5A (21). 
Therefore, we sought to understand whether the mechanism of action of ROR2 blockade on 
chondrogenic differentiation was through regulation of YAP signaling. In keeping with this 
hypothesis, WNT5A treatment of C3H10T½ cells increased the proportion of cells with a 
nuclear YAP staining pattern within 4 hours (Fig. 6E and F and fig. S9A). In addition, ROR2 
overexpression in C28/I2 chondrocytes (which do not express ROR2 endogenously) in the 
presence of WNT5A resulted in an increased proportion of cells with prevalently nuclear YAP 
staining (Fig. 6G and H and fig. S9B and C) and in increased intensity of nuclear YAP staining 
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(Fig. 6I and fig. S9D). Importantly, the nuclear localization of YAP was inhibited by the Gi/o-
protein inhibitor pertussis toxin and the Rho inhibitor CT04 (Fig. 6G to I and fig. S9B to D) 
thereby suggesting that, as previously reported for ROR1 (21), ROR2-mediated YAP activation 
requires G-protein-coupled receptors and Rho. This mechanism is consistent with the correlation 
of WNT5A with YAP and CTGF in cartilage from patients with osteoarthritis, with the similar 
temporal dynamics of  Yap, Ctgf, Ror2 and Wnt5A in the destabilization of the medial meniscus 
(DMM) model, and with our finding that ROR2i caused downregulation of CTGF in the articular 
cartilage in vivo.  
Finally, we investigated whether YAP downregulation is required for the chondrogenic 
effect of ROR2i. In keeping with this hypothesis, overexpression of constitutively active YAP 
(S127A YAP) partially reverted the upregulation of Sox9 induced by ROR2 silencing (Fig. 6J). 
However, inhibiting YAP signaling directly using verteporfin, an inhibitor of the binding of YAP 
with TEAD, was not sufficient to induce chondrogenesis (Fig. 6K). Taken together, these data 
indicate that ROR2 regulates YAP through G-proteins and Rho (Fig. 6L), and that YAP 
inhibition is required for the chondrogenic differentiation induced by ROR2 blockade (fig. S10). 
 
Discussion 
We have shown that in osteoarthritis ROR2 signaling is associated with cartilage breakdown. 
ROR2 gain of function inhibited chondrocytic differentiation, whereas loss of function promoted 
chondrogenesis and, in vivo, improved pain and structural outcomes in osteoarthritis models. 
ROR2i was not associated with systemic or local toxicity. ROR2 blockade did not affect 
canonical WNT signaling but reduced YAP signaling in a Rho- and G-protein-dependent manner 
(fig. S10). YAP inhibition was required for the chondrogenic function of ROR2i but was not 
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sufficient per se to induce chondrogenesis. The requirement of G-proteins suggests that, as in the 
case of ROR1 (21), ROR2 requires a G-protein-coupled co-receptor, most likely FZD (21). 
Similarly, the requirement of Rho in ROR2 signaling has been documented in other contexts 
including skeletal development (18, 56) and Rho was essential for the capacity of ROR1 to 
upregulate YAP (21). The distinct function of ROR2 makes it a useful targeting opportunity in a 
highly redundant system such as WNT signaling. Targeting any of the many ligands of ROR2, 
including WNT3A, -5A, -11 and-16 (18) which are all expressed in cartilage, would likely result 
in compensation. 
In addition to a disease-modifying effect, ROR2 blockade achieved striking and rapid 
symptomatic relief. This is an important characteristic from the translational point of view, not 
only because it would result in immediate benefit for patients, but also because it will warrant 
compliance and ultimately success in clinical trials where pain is usually a primary outcome. The 
absence of side effects also makes ROR2i stand out compared to other chondrogenic 
interventions such as BMPs or TGF-β, which are potent chondrogenic factors but can induce 
ectopic cartilage and bone formation (57–59) and play a role in several other organs. For 
instance, activation of TGF-β signaling leads to pulmonary fibrosis and a scleroderma-like 
syndrome (60). Mammalian target of rapamycin (mTOR) inhibition with rapamycin protects 
mice from osteoarthritis (61), but rapamycin, also used as an anti-cancer drug, has severe side 
effects. In our study we treated mice for ten weeks without observing any obvious side effects or 
toxicity, including kidney and liver function tests. Furthermore, patients with recessive Robinow 
syndrome, who have loss of function mutations to both ROR2 alleles (27), have no overt 
phenotype which cannot be ascribed to developmental defects. Therefore, no major side effects 
should be expected by ROR2 blockade in adulthood. Moreover, we show that ~50% silencing in 
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the joint is sufficient to improve outcomes of osteoarthritis, suggesting that the functions of 
ROR2 that are not compensated by a 50% reduction are unlikely to result in toxicity. This is an 
important advantage of targeting ROR2 for osteoarthritis, which, despite being a severe disabling 
disease, it is not a life-threatening one. Along the same line, the technology we used to block 
ROR2 signaling in vivo employed two components, siRNA and atelocollagen, which are already 
used in clinical settings, the former in various diseases (62–64) and the latter as a filler in 
aesthetic surgery. Although other targeting strategies are possible, such as a ROR2 blocking 
antibody, atelocollagen-conjugated siRNA proved to be efficient in engaging with its target 
within cartilage, where the dense, avascular ECM impedes efficient penetration of many 
synthetic or natural biomolecules (41, 65).  
Some limitations of this study should be acknowledged. Therapeutically, a treatment regimen of 
weekly intra-articular injections is unfeasible in patients, therefore we acknowledge that re-
formulation, for example by stabilizing the siRNA, or slow release methods would be required 
before ROR2 blockade can be used clinically. In addition, many patients with osteoarthritis have 
several joints that are affected; to treat such patients, systemic delivery would be preferable. 
Finally, we validated ROR2i in a model of instability-induced osteoarthritis. Whether ROR2i 
would be effective in patients whose osteoarthritis is driven by different mechanisms - obesity, 




Materials and methods 
Study Design 
The objective of this study was to develop and evaluate ROR2 blockade as a therapy for 
osteoarthritis. This study consisted of in vitro and in vivo experiments using samples from 
patients with end-stage osteoarthritis, or C57BL/6 mice that had undergone a surgical 
osteoarthritis models. Primary cells from patients, C3H10T½ (ATCC), HEK293 cells (ATCC) or 
C28/I2 (66) were used for in vitro experiments. When melting curves in the real-time PCR 
reaction indicated abnormal/non-specific amplification, the sample was not included in the 
subsequent analysis. Similarly, when micromasses became detached or broken during 
processing/staining, they were removed from analysis. ROR2 expression in osteoarthritis was 
observed before controlled laboratory experiments were carried out to assess the impact of gain 
or loss of ROR2. A surgical model of osteoarthritis, the menisco-ligament injury model, was 
performed in mice. Treatment was delivered using atelocollagen-conjugated siRNA (scrambled- 
or ROR2-siRNA). Animal sample size was calculated on the basis of a small-scale MLI study. 
Mice were randomly allocated to treatment groups (control, ROR2i or crossover) across cages. 
Health scores were monitored every 5 days from start of treatment and incapacitance was 
measured throughout the study. The investigators administering intra-articular injections and 
measuring incapacitance were blinded to the treatment. Safranin O staining was carried out in 
batches at random, across treatment groups. When cutting, staining, scoring, and conducting 
histomorphometrical assessments, the investigators were blinded to treatment. Scoring of 
osteoarthritis severity was conducted by two independent assessors. Due to repeated injections 
and fighting, some mice developed local inflammation and skin lesions. These were scored 
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according to severity (fig. S11, table S2), and mice that had a score above 3 more than once were 
excluded from analyses. These reactions were independent of treatment group (8 control, 5 
ROR2i and 7 crossover mice were excluded). Mice with <3 intact sections for assessment of 
osteoarthritis severity were excluded. In fig. S7, one mouse from the control group was identified 
using Grubb’s test for outliers in R (P = 0.041; (67, 68)), and was removed from analyses 
because it had not developed osteoarthritis.  
Cartilage harvest, chondrocyte isolation and culture 
Adult human articular cartilage and synovial membrane were obtained from femoral condyles 
following informed consent from four patients undergoing joint replacement for knee 
osteoarthritis. Individual number of patient samples indicated in figure legends.  All procedures 
were approved by the East London and The City Research Ethics Committee 3 (ethics approval 
REC N. 07/Q0605/29). Full thickness explants were prepared for histology and scored for 
features of osteoarthritis as previously described (50, 69). Cartilage and synovium lysates from 1 
patient were harvested in radioimmunoprecipitation assay buffer (RIPA) at time of dissection 
and prepared for western blotting. Chondrocytes and SM-MSCs were isolated and expanded in 
vitro as previously described (36, 38). SM-MSCs were differentiated to chondrocytes using 10 
ng/ml TGF-β1 (R&D) in micromass culture for 6 days (38). 
Micromass culture and Alcian blue staining 
C3H10T½ cells were plated in micromass as previously described (39, 70). When indicated, 
micromasses were cultured with 100 ng/ml BMP2 (R&D) or 7 μM Verteporfin (Sigma) or 
vehicle. After 3 days, micromasses were harvested for real-time PCR gene expression analysis or 
fixed and whole-mount stained with Alcian blue. Images were acquired at room temperature with 
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a Leica DFC295 camera on a dissecting microscope. Alcian blue staining, extraction and 
quantification was performed as previously described (49, 70). Densitometry of the micromasses 
was measured using ImageJ (71), by placing all images on a single canvas, splitting into hue, 
saturation, brightness (HSB) stacks and analyzing the “Saturation” stack with the gel tool. The 
entire micromass was selected for analysis. 
Murine femoral hip cap avulsion model 
Murine femoral head articular cartilage was explanted from the bone as described previously (11, 
72, 73). From each mouse, one hip cap was immediately embedded in optimal cutting 
temperature compound (OCT; Tissue-Tek) and frozen, and the contralateral hip cap was rested 
ex vivo for the indicated time in complete culture medium, before being harvested for 
immunofluorescence.  
Overexpression and siRNA transfection 
Subconfluent cells were transfected with plasmids or siRNA using JetPRIME transfection 
reagent (PolyPlus), as previously described (49). pEF1a-mRor2WT was a gift from Roel Nusse 
(Addgene plasmid # 22613 ; http://n2t.net/addgene:22613 ; RRID:Addgene_22613) (51). 
pCMV-flag S127A YAP was a gift from Kunliang Guan (Addgene plasmid # 27370 ; 
http://n2t.net/addgene:27370 ; RRID:Addgene_27370) (74). An empty vector was used as a 
negative control, and enhanced green fluorescent protein (eGFP) to monitor transfection 
efficiency. ROR2 siRNA was synthesized with Ambion Silencer siRNA synthesis kit (Thermo 
Fisher), and used at a final concentration of 20 nM. A scrambled sequence with the same GC 
content was used as a negative control. BLOCK-iT fluorescent oligo (Thermo Fisher) was used 




Lentiviral ROR2- or control shRNA were used as per manufacturer's instructions (TL502626; 
Origene).  
Total RNA extraction and real-time PCR 
RNA extraction, reverse transcription and gene expression analysis were performed as 
previously described (50). Primers are listed in table S3. 
SUPER8XTopflash assay 
Cells were co-transfected with SUPER8XTOPFlash TCF/LEF-firefly luciferase reporter plasmid 
(Kind gift from Dr Muy-Teck Teh), CMV-Renilla luciferase plasmid (Promega) and any other 
plasmids indicated in figures. 24 hours later, cells were stimulated with 100 ng/mL recombinant 
WNT3A (R&D), 100 ng/mL recombinant WNT5A (R&D), 5 μM BIO (Sigma) or their 
respective vehicles for 24 hours before luciferase activity was measured using the Dual 
Luciferase Reporter assay system (Promega).   
Western blot analysis 
Western blots were carried out as described previously (75). Membranes were blocked and 
antibodies diluted in 3% nonfat milk/1% bovine serum albumin/0.01% Tween 20 in phosphate 
buffered saline (PBS). Primary antibodies used were mouse anti-ROR2 (deposited to the 
Developmental Studies Hybridoma Bank (DSHB) by Nusse, R. DSHB Hybridoma Product 
Ror2), diluted 1:500 and mouse anti–β-actin (Sigma), diluted 1:5000. Horseradish peroxidase 
(HRP)-conjugated secondary antibodies (Santa Cruz Biotechnology) were diluted 1:2000. 
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Protein expression was quantified by analyzing the densitometry of bands using ImageJ (71), and 
normalized for β-actin. 
Immunocytochemistry 
For immunofluorescence study, cells were transfected if indicated and then grown on chamber 
slides (Nunc Lab-Tek, Merck) or 96-well plates. For immunofluorescence study of YAP, cells 
were serum-starved for 16-24 hours, pre-treated with the Rho inhibitor CT-04 (2 ug/mL, 
Cytoskeleton Inc), pertussis toxin (Ptx, 100 ng/mL, Sigma) or vehicle for 2 hours if indicated, 
and then stimulated with recombinant WNT5A (100 ng/mL, R&D), Lysophosphatidic Acid 
(LPA, 20 𝜇M, Santa Cruz Biotechnology) or vehicle for 4 hours. Cells were washed with PBS, 
fixed and permeabilized with ice-cold methanol and stained as described below. 
Indirect immunofluorescence 
Indirect immunofluorescence was performed as previously described (75). For antigen retrieval 
on paraffin sections, pepsin or proteinase k digestion were used. The primary anti-ROR2 mouse 
monoclonal antibody, deposited to the DSHB by Nusse, R. (DSHB Hybridoma Product Ror2), 
was diluted 1:100, primary anti-YAP (14074S, CST) was diluted 1:100. Primary anti-CTGF was 
generated and diluted 1:1000. The CTGF antiserum was raised in sheep (Micropharm) against 
CPGDNDIFESLYYRKMYGDMA (CTGF [329–349]; UniProtKB - P29279 human CTGF) 
synthesized by Bachem AG. The peptide (96% purity) was conjugated through N-terminal Cys 
to carrier protein pre-reacted with N-succinimidyl 4-(4-maleimidophenyl)butyrate following 
previously described methodologies (76). Isotype-matched non-immune immunoglobulin (IgG) 
controls were used at the same concentration. Secondary antibodies were cy3- goat anti–mouse 
antibody (Jackson ImmunoResearch Laboratories) diluted 1:300, donkey anti-sheep Alexa 555 
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or donkey anti-rabbit Alexa 555 (Life Technologies) diluted 1:1000. Nuclei were counterstained 
using 4′,6-diamidino-2-phenylindole (dapi) or with fluoroshield mounting medium containing 
dapi (Merck). Images were acquired using an Olympus BX61 microscope with a fixed exposure 
using either 10×/0.4, 20×/0.7 or 40x/0.85 objective lenses using Cell-Sense software. Images 
were enhanced using Adobe Photoshop for better rendering without altering relationship of target 
to control images. Quantification of staining was performed using ImageJ (71). Images were 
thresholded without altering relationship of target to control images, and the cartilage was 
selected as a region of interest based on the Nomarski image. Max-min grey values of the 
fluorescent image alone were normalized by the area for each image, and the IgG control was set 
as baseline. Alternatively, the cell counter plugin was used to quantify the number of cells 
positive for CTGF within the region of interest and normalized by the total number of cells 
within this region.  
 
For confocal images, Z-stacks were collected using the 40x objective of a Zeiss LSM510 laser 
scanning confocal microscope.  All confocal image acquisition settings were constant throughout 
the experiment. 
Quantification: for each cell, the ideal plane along the z axis was chosen as that with the brightest 
staining and the larger area. The blue and the red channels were enhanced individually for best 
rendering (this does not affect the measured intensity) so that the entire cell was visible in the red 
channel. The average intensity of the nuclear YAP staining was measured by drawing the largest 
circle fitting into the nucleus and noting the average intensity value. The average total staining 
was obtained by manually contouring the cell and reading the intensity value. The average 
staining intensity of the brightest part of the cytoplasm was also noted. For the staining pattern, 
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cells were classified as having a prevalently nuclear YAP staining if, by toggling the dapi 
channel off, the nucleus was clearly identified as a hyper-stained area; as prevalently cytoplasmic 
if the nucleus was clearly identified as a hypo-stained area, and diffused when the area of the 
nucleus was not identified unless the dapi channel was on. The cells with a prevalently 
cytoplasmic staining were given a score of 0, cells with a diffuse staining a score of 1 and cells 
with a prevalently nuclear staining a score of 2. 
Animals 
All animal procedures were approved by the Local Ethics committee and the UK Home Office 
(PPL 70/7986). Mice were kept in an approved animal care facility and were housed 6 per cage 
in standard, individually ventilated cages. C57BL/6 and CD1nu/nu mice were obtained from 
Charles River. 
Atelocollagen-conjugated siRNA in vivo 
An equal volume of atelocollagen (Koken and siRNA were combined by rotation at 4 ᵒC for 20 
minutes as described (42), to final concentrations of 0.5% atelocollagen and 20 μM siRNA. 7 μl 
Atelocollagen-conjugated ROR2- or scrambled-siRNA was injected intra-articularly, bilaterally, 
while mice were under anesthesia. Mice were euthanized after 5 or 7 days. Femoral condyles 
were fixed in 4% paraformaldehyde in PBS at pH 7.4, decalcified, paraffin embedded, sectioned 
and used for immunofluorescence staining. All tissues between the menisci and tibial growth 
plate were harvested for protein expression analysis by western blot.   
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Destabilization of the medial meniscus 
Osteoarthritis was induced in 10 week old male C57BL/6 mice by destabilization of the medial 
meniscus (DMM) as previously described (77). Contralateral knees were sham-operated as 
internal controls. Mice were euthanized 7 days after surgery. 
Menisco-ligament injury 
Osteoarthritis was induced in 10 week old male C57BL/6 mice by menisco-ligament injury 
(MLI), which consisted of surgical resection of the anterior horn of the medial meniscus and of 
the medial collateral ligament (44–47). Contralateral knees were sham-operated or unoperated. 
After 2 or 4 weeks as indicated, mice were injected bilaterally with 7 μl atelocollagen-conjugated 
siRNA every 5 days. Mice were euthanized 8 or 12 weeks after surgery. Blood was collected by 
cardiac puncture for serum analysis (MRC Harwell clinical pathology laboratory).  
Incapacitance 
Incapacitance was measured throughout the study using a Linton incapacitance meter (45). 
Measurements were taken over 3 seconds and 10 readings per mouse were taken at each time-
point. For each mouse, the mean incapacitance was calculated at each time-point. The area under 
the curve from 35- 81 days after surgery for each mouse was calculated as indicated. To avoid 
confounding factors such as short-term inflammation caused by the intra-articular injections, 
measurements were taken at least 48 hours after injection. 0.1 mg/kg buprenorphine or an equal 
volume of sterile PBS (vehicle) was injected subcutaneously, and 1 hour later incapacitance was 




After dissection and fixing in 4% paraformaldehyde overnight, knee joints were stored in 70% 
alcohol and scanned with a Bruker Skyscan 1272 with the following parameters: 40 kV, 250 μA, 
Aluminium 0.5 mm filter; 0.6° rotation angle, no frame averaging and an isotropic 4.5 μm voxel 
size. Each dataset was rotated in Dataviewer (Skyscan) to ensure similar orientation and 
alignment for analysis, as previously described (78). Hand-drawn regions of interests (ROI) of 
the medial tibial epiphyseal bone fraction were selected in the posterior compartment in CTAn 
(Skyscan), demarcated by the joint space proximally and distal limits defined by the growth 
plate. Analysis was achieved using 3D algorithms in CTAn to provide bone volume fraction 
(BV/TV). 
Histological analysis and osteoarthritis scoring 
Knees were prepared for histology as previously described (75, 79). All images were taken using 
the same settings on an Olympus BX61 microscope and osteoarthritis severity was assessed 
using the OARSI scoring system (80). Histomorphometrical analysis of Safranin O staining, 
subchondral bone thickness, synovial thickness and osteophytes were carried out as described in 
supplementary methods, fig. S12.  
In vivo ectopic cartilage formation assay 
The ectopic cartilage formation assay was modified from previously described protocols (36, 49, 
50). Freshly isolated human articular chondrocytes were transduced with a ROR2- or control-
shRNA lentivirus and passaged once. For each injection 1 million transduced chondrocytes were 
resuspended in 100 µL of sterile PBS/ type 1 collagen (Corning) and injected subcutaneously in 
the back of  3-week-old female CD1nu/nu mice. After two weeks the mice were sacrificed and 
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cartilage implants were retrieved. The implants were embedded in OCT and stained with 
Toluidine Blue for histological analysis (supplementary methods, fig. S13).  
Statistical analysis 
All figures show individual data points. Where there are no boxplots, the error bars represent 
standard error of the means except in figures 4E and S7B where they represent 95% confidence 
intervals. Parametric data were compared with student’s t-test. For multiple comparisons, 
analysis of variance (ANOVA) test followed by Tukey’s honest significant difference (HSD) 
post hoc test for multiple comparisons. For non-parametric data, Kruskall-Wallis test with 
Dunn’s post-test and Benjamini- Hochberg correction for multiple comparisons were used. 
Microarray data was analyzed with linear modelling (limma) with Benjamini Hochberg 
correction for multiple comparisons.  Incapacitance data were analyzed with a mixed effect 
linear model with pairwise comparisons at the different time points (Tukey correction of P 
values for multiple comparisons). The proportion of nuclear/cytoplasmic YAP staining was 
compared using a generalized linear model. Tests were two-sided and P values <0.05 were 
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Fig. 1. ROR2 expression is upregulated in osteoarthritis 
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(A) ROR2 expression (red) in the periarticular perichondrium and joint interzone of a murine 
paw at 18.5 days post coitum (dpc). Dapi (blue), bars, 100 µm. (B) Immunostaining of ROR2 
(red) in murine articular cartilage one week after destabilization of the medial meniscus (DMM) 
compared to sham-operated control joint. Bars, 50 µm; F, femur; M, meniscus; T, tibia. Insets 
shown at higher magnification on right. (C) ROR2, WNT5A, YAP and CTGF expression in 
human osteoarthritic cartilage (OA) versus healthy normal cartilage, n=12, linear modeling 
(limma) with Benjamini-Hochberg correction for multiple comparison. WNT5A P = 0.00028, 
CTGF P = 0.028, YAP P = 0.000036. Box and whiskers plots show all values, line at the median, 
boxes extend from the 25th to 75th percentiles, error bars span max to min values (29). (D) 
ROR2 expression (red) in full-thickness human articular cartilage from a patient undergoing total 
knee replacement for osteoarthritis. Bars, 200 µm. (E) Western blot for ROR2 in articular 
cartilage and synovium from a patient undergoing total knee replacement for osteoarthritis, n=1. 
Whole cell lysate of C3H10T½ cells and C28/I2 cells were used as positive and negative 
controls, respectively. (F) Temporal regulation of Ror2, Wnt5A, Yap and Ctgf in the murine joint 
after DMM, GEO accession GSE41342, n= 9 mice at each timepoint. Circles show mean, error 
bars are standard error of the mean, two-way ANOVA with Tukey’s HSD post-hoc test (# in 
black refers to differences between DMM vs unoperated controls, or in yellow between sham-
operated vs unoperated controls, * between DMM vs sham), Ror2 ### P = 0.00039, ## P = 
0.0079, ** P = 0.0054; Wnt5A # P = 0.016, * P = 0.032; Yap ## P = 0.0011, # P = 0.017, 16-
week sham # P = 0.031, ** P = 0.0014. (G) ROR2 and WNT5A expression in human articular 
chondrocytes stimulated with 10 µM IL-1β for 24 hrs. GEO accession GSE75181, n=12 patients, 
line at mean, error bars show standard error of the mean, class comparison test based on a paired 
t-test with Benjamini-Hochberg correction, *** P = 0.00079, **** P = 0.00000026. (H) ROR2 
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expression (red) in murine femoral hip caps explanted from subchondral bone and cultured ex 
vivo for indicated times. Bars, 25 µm.  (I) Quantification of the ROR2 staining in the articular 
cartilage, from images in fig. S2B. n= 7 (0 days), 4 (1 day) and 3 (7 days) hip caps, line at mean, 
error bars show standard error of the mean, ANOVA with Tukey’s HSD post-hoc test, * P = 





Fig. 2. ROR2 overexpression inhibits chondrogenesis  
(A) Glycosaminoglycan content in C3H10T½ cells transfected with ROR2 or empty vector, 
cultured in micromass for 3 days ±100 ng/ml BMP2 and stained with Alcian blue. Extracted 
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Alcian blue was quantified. n=4, line at mean, error bars show standard error of the mean, two-
way ANOVA with Tukey’s HSD post-hoc test, * P = 0.033, all other comparisons **** P 
<0.0001. (B) Representative images of Alcian blue staining from (A). (C-H) Chondrogenic 
differentiation markers in C3H10T½ cells transfected with ROR2 or empty vector and cultured 
in micromass for 3 days, gene expression compared by real-time PCR analysis. n=2-4, line at 
mean, error bars show standard error of the mean, unpaired t-test, ** P = 0.0024, ## P = 0.0031, 
$$ P = 0.0019. Col2a1, collagen type II; Acan, Aggrecan; Col1a1, collagen type I; ColX, 





Fig. 3. Silencing ROR2 induces chondrogenesis 
(A) Real-time PCR analysis showing Ror2-silencing efficiency of lentiviral ROR2 shRNA in 
C3H10T½ cells. n=3-4, unpaired t-test, * P = 0.033, $$ P = 0.0034. (B) Glycosaminoglycan 
content in C3H10T½ cells transfected with ROR2- or scrambled siRNA cultured in micromass 
for 3 days ±100 ng/ml BMP2. Micromasses were stained with Alcian blue and compared by 
densitometry, n=4, two-way ANOVA with Tukey’s HSD post-hoc test, *** P = 0.00040, ## P = 
0.0072. (C) C3H10T½ cells expressing ROR2- or control shRNA were cultured in micromass 
 
41 
for 3 days and stained with Alcian blue. Extracted Alcian blue was quantified and normalized for 
DNA content, n=4. Representative images shown below. Unpaired t-test, P = 0.013. (D) PCR 
and densitometric quantification of Acan in C3H10T½ cells transfected with ROR2- or 
scrambled siRNA and cultured in micromass for 3 days, n=3. Unpaired t-test, P = 0.023. (A-D) 
line at mean, error bars show standard error of the mean. (E) Molecular markers of 
differentiation and proliferation in C3H10T½ cells transfected with ROR2- or scrambled siRNA 
and cultured in micromass for 3 days, n=4-5. Box and whiskers plots show all values, line at the 
median, boxes extend from the 25th to 75th percentiles, error bars span max to min values, 
unpaired t-test, P = 0.049. (F) Adamts-4 and Adamts-5 expression in C3H10T½ cells expressing 
ROR2- or control shRNA.  Cells were cultured as in (C) and gene expression compared by real-
time PCR analysis. n=3-4, line at mean, error bars show standard error of the mean, unpaired t-





Fig. 4. ROR2 blockade improves pain and structural outcomes of osteoarthritis in mice 
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(A) ROR2 expression in the tibia 5 days after intra-articular injection of 20 μM ROR2 siRNA 
conjugated to 0.5% atelocollagen in mice. Western blot and densitometric quantification, values 
were normalized for actin, n=4. Images closest to the median are shown, all replicates are in fig. 
S5. Box and whiskers plots show all values, line at the median, boxes extend from the 25th to 75th 
percentiles, error bars span max to min values. (B) CTGF expression (red), dapi (blue) in femoral 
condyles 5 days after intra-articular injection with ROR2- or scrambled siRNA conjugated to 
0.5% atelocollagen in mice. IgG, isotype control; AC, articular cartilage; B, bone; dotted line 
indicates the osteochondral junction; bars, 50 µm. (C) The percentage of cells expressing CTGF 
in the articular cartilage in (B), n=4, box and whiskers plots show all values, line at the median, 
boxes extend from the 25th to 75th percentiles, error bars span max to min values. (D) 
Experimental scheme. Two weeks after menisco-ligament injury (MLI) surgery, ROR2i or 
scrambled (control) siRNA was injected intra-articularly for ten weeks; d, day, n= 7 (control), 10 
(ROR2i), 8 (crossover). (E) Percentage of bodyweight loaded on the operated leg. Blue dotted 
line indicates surgery, black arrow indicates start of treatment, blue arrow indicates treatment 
switch for the crossover group. Circles show mean, error bars show 95% confidence intervals. 
Mixed effect linear model with pairwise comparisons at the different time points (Tukey 
correction of P-values for multiple comparisons). P-values at timepoints shown in figure. (F) 
Incapacitance at day 81 (final time-point). Box and whiskers plots show all values, line at the 
median, boxes extend from the 25th to 75th percentiles, error bars span max to min values. 
ANOVA with Tukey’s HSD post-hoc test, control vs ROR2i P = 0.0030, ROR2i vs crossover P 
= 0.036. (G) The area under the curve of incapacitance was calculated starting from day 35. Box 
and whiskers plots show all values, line at the median, boxes extend from the 25th to 75th 
percentiles, error bars span max to min values. ANOVA with Tukey’s HSD post-hoc test, control 
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vs ROR2i P = 0.00019. (H) Incapacitance was measured before, and 1hr after administration of 
0.1 mg/kg buprenorphine (analgesic) or saline (vehicle), n=4, all data points shown, lines 
connect paired samples. Mann-Whitney U test, P = 0.016.  (I) Representative images of Safranin 
O staining of the medial compartment; F, Femur; T, Tibia; M, Meniscus; bars, 200 µm. (J) 
Osteoarthritis severity was assessed using the Osteoarthritis Research Society International 
(OARSI) scoring system. Box and whiskers plots show all values, line at the median, boxes 
extend from the 25th to 75th percentiles, error bars span max to min values. Kruskal-Wallis with 
Dunn’s post-test and Benjamini-Hochberg multiple correction, Tibia * P = 0.031, # P = 0.040, 
Summed * P = 0.041, # P = 0.031. (K) Quantification of structural integrity and proteoglycan 
content of the articular cartilage, assessed by histomorphometrical analysis. Box and whiskers 
plots show all values, line at the median, boxes extend from the 25th to 75th percentiles, error bars 
span max to min values. Mann-Whitney U test, P = 0.026. (L) Weight gain of mice over 10 





Fig. 5. ROR2 blockade enhances human cartilage formation in vivo 
Human articular chondrocytes were transduced with ROR2 or control shRNA and implanted 
subcutaneously in the backs of nude mice. Two weeks later, cartilage implants were retrieved. 
(A) Toluidine blue staining of cartilage-specific highly sulphated glycosaminoglycans (purple) in 
the implants. Images closest to the median are shown, bars, 200 μm. (B) Histomorphometric 
analysis of the differentiated area normalized for total area, n=6, line at mean, standard error of 





Fig. 6. ROR2 blockade increases chondrogenic differentiation through YAP 
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TOPFlash reporter assay in (A) HEK293 cells transfected with an empty vector (EV) or ROR2 
and stimulated with 100 ng/mL WNT3A, WNT5A, both or vehicle. Box and whiskers plots 
show all values, line at the median, boxes extend from the 25th to 75th percentiles, error bars span 
max to min values. n = 4, ANOVA with Tukey’s HSD post-hoc test, ** P =  0.0011, ### P = 
0.00079, $$$ P = 0.0010, **** and #### P < 0.0001. (B) in C3H10T½ cells transfected with an 
empty vector (EV) or ROR2 and stimulated with 100 ng/mL WNT3A, WNT5A, both or vehicle.  
(C) in C3H10T½ cells transfected with an empty vector or ROR2 and stimulated with 5 μM BIO 
or vehicle and (D) in C3H10T½ cells expressing shControl or shROR2 and stimulated with 100 
ng/mL WNT3A, WNT5A, both or vehicle. (B-D) n=4, line at mean, error bars show standard 
error of the mean, 2-way ANOVA with Tukey’s HSD post-hoc test, ## P = 0.010, ### P = 
0.0001,  **** P < 0.0001, *** P = 0.0001, ** P = 0.0081, ND= no significant difference. (E) 
Immunofluorescence for YAP (red) in C3H10T½ cells stimulated with 100 ng/mL WNT5A or 
vehicle for 4 hours, dapi (blue), bars, 50 µm. (F) Quantification of the proportion of cells with 
prevalent nuclear, diffuse, or cytoplasmic staining. Individual cells were given a score of 0 
(cytoplasmic), 1 (diffuse), or 2 (prevalently nuclear) and a generalized linear model was fit to 
compare the groups followed by a post-hoc pairwise comparison (Tukey correction), **** P < 
0.0001 for all comparisons. 7-18 cells per condition were scored. (G) Immunofluorescence for 
YAP (red) in C28I/2 cells transfected with empty vector or ROR2, pre-treated with 2 μg/mL 
CT04, 100 ng/mL PTX or vehicle for 2 hours and stimulated with inhibitors and 100 ng/mL 
WNT5A for 4 hours, dapi (blue), bars, 50 µm. (H) Quantification of the proportion of cells with 
prevalent nuclear, diffuse, or cytoplasmic staining. 3-18 cells per condition were scored. 
Individual cells were given a score of 0 (cytoplasmic), 1 (diffuse), or 2 (prevalently nuclear) and 
a generalized linear model was fit to compare the groups followed by a post-hoc pairwise 
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comparison (Tukey correction). Vehicle vs WNT5A P = 0.0003, WNT5A vs ROR2 P = 0.0004, 
WNT5A vs ROR2 + WNT5A P = 0.0003, ROR2 vs ROR2 + WNT5A + CT04 P = 0.0004, 
ROR2 vs ROR2 + WNT5A + PTX P < 0.0001, ROR2 + WNT5A vs ROR2 + WNT5A +CT04 P 
= 0.0003, ROR2 + WNT5A vs ROR2 + WNT5A + PTX P = 0.0002, (I) Intensity of YAP 
staining within the nucleus in C28I/2 cells treated as in (G), n= 3-18, box and whiskers plots 
show all values, line at the median, boxes extend from the 25th to 75th percentiles, error bars span 
max to min values. ANOVA with TukeyHSD post-hoc test on logged values, * P = 0.012, ** P = 
0.0015, *** P = 0.00012, **** P < 0.0001. (J) C3H10T½ cells expressing shROR2 or control 
shRNA were transfected with an empty vector (EV) or S127A YAP (constitutively active YAP) 
and cultured in micromass for 3 days. Gene expression was compared by real-time PCR analysis, 
data from two independent experiments were scaled and combined. Box and whiskers plots show 
all values, line at the median, boxes extend from the 25th to 75th percentiles, error bars span max 
to min values. Two-way ANOVA with Tukey’s HSD post-hoc test. P = 0.024, ND = no 
significant difference. (K) C3H10T½ cells were cultured in micromass for 3 days with 100 ng/ml 
BMP2, 7 μM Verteporfin (YAP inhibitor), or vehicle. Micromasses were stained with Alcian 
blue and compared by densitometry. Representative images are shown below, bars 2 mm, n=4, 
line at mean, error bars show standard error of the mean. ANOVA with Tukey’s HSD post-hoc 
test, ** P = 0.0070, **** P < 0.0001. (L) ROR2 signaling after cartilage injury: WNT5A 
activates ROR2, which, through the co-operation of G-protein coupled receptors (GPCR) and 







Histomorphometrical analysis of cartilage 
Safranin O staining was carried out in batches at random, across treatment groups. All images 
were taken using the same settings and exposure, with any auto‐enhancing features of the camera 
and of the acquisition program turned off, which, by normalizing the total luminosity and 
contrast, or modifying the colours, might reduce the differences and therefore lead to false‐
negative results. 
A global scale was set in ImageJ using the scale bar. Each image was then opened in ImageJ (fig. 
S12A) and rotated so that a line drawn along the cartilage‐bone junction in the middle of the 
plateau is perfectly horizontal (fig. S12B). This is very important so that non‐cartilage staining in 
the bone marrow spaces can be eliminated (see below). This was accomplished by drawing a line 
with the line tool and noting the angle as doing so. The image was then rotated by this angle. 
Then, the tibial plateau was selected using a polygon or free‐hand tool, including any 
osteophytes, the growth plate and up to the end of the cartilage (fig. S12C). The selection was 
copied, and all sections placed on a single large canvas, aligned horizontally (fig. S12D). 
To isolate the metachromatic Safranin O staining from the background and most of the 
orthochromatic staining (subchondral bone) the RGB image was transformed into a hue, 
saturation, brightness (HSB) stack (Image>Type>HSB Stack), and the “Saturation” slice 
selected. This abolishes background and staining of the bone (fig. S12E). 
Setting the region of interest (fig. S12E): a rectangle 600 microns wide and the full height of the 
canvas was made. The rectangle was placed over the first section to include the tibial plateau, 
making sure to exclude any osteophyte (left side in this figure) and the “bulgy” part near the 
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intercondylar notch. Osteophytes are best identified in the original figure rather than in the 
“Saturation” slice. Press Ctrl+1. Slide the rectangle laterally over the next section and press 
Ctrl+2. This was done for each section and, when over the last section, Ctrl+3 were pressed. 
This plots the density profile of each section (fig. S12F). The first negative peak is the articular 
cartilage. 
One horizontal line was drawn to cut the residual background, if any, and lateral lines to limit the 
articular cartilage peak (fig. S12G) and eliminate the staining of the bone marrow spaces. This 
was repeated for each profile of the sections in the same canvas. Using the “Wand” tool and 
clicking inside the area under the curve in each of the density profiles highlighted the area under 
the curve and returned the area measurement. These results were copied from the measurements 
box into a statistics programme to calculate the median. The median of all the sections of each 
knee was utilised for that individual knee.  
Sections with cutting or staining artefacts (understained or saturated) were excluded, and knees 
with less than 3 intact sections were excluded. For optimum consistency there should be 4‐6 
sections covering 200 microns around the centre of the tibial plateau. The central section is 
identified as the one with the shortest cross section of the medial meniscus. 
R script for further analysis can be supplied upon request. 
  
Subchondral bone measurement 
Ensuring that a global scale had been set for all images, using the rotated image (fig. S12B), five 
measurements of the subchondral bone were taken. Measurements were taken perpendicular to 
the cartilage-bone junction and went to the top of bone marrow, or if there was no bone marrow, 
to the growth plate (fig. S12H). Analyse > Measure returned the length of the lines (fig. S12I). 
 
51 
These results were copied from the measurements box into a statistics programme to calculate 
the mean subchondral bone thickness (microns) for each image. The mean of all images from 
each knee was utilised for that individual knee. Subchondral bone thickness was measured from 
at least 3 sections of each knee. 
R script for further analysis can be supplied upon request. 
  
Synovium measurement 
In a similar way as for the subchondral bone and as described by Valverde-Franco et al., 
ensuring that a global scale had been set, synovial thickness was measured by drawing a line that 
went horizontally through the synovial lining (fig. S12J). Analyse > Measure returned the length 
of the lines. These results were copied from the measurements box into a statistics programme to 
calculate the mean synovial thickness (microns) for each image. The mean of all images from 
each knee was utilised for that individual knee. Synovial thickness was measured from at least 3 
sections of each knee. 
R script for further analysis can be supplied upon request. 
  
Osteophyte measurement 
Ensuring that a global scale had been set for all images, using the rotated image (fig. S12B), 
medial tibial osteophytes were selected with the polygon or free‐hand tool (fig. S12K). Having 
set the measurements to include Area and Perimeter, Analyse > Measure returned these 
parameters. These results were copied from the measurements box into a statistics programme to 
calculate the mean area and perimeter of the osteophyte (in microns) for each image. The mean 
 
52 
of all images from each knee was utilised for that individual knee.  Osteophytes from at least 3 
sections of each knee were measured. 
R script for further analysis can be supplied upon request. 
 
Quantification of Toluidine Blue staining 
Using Toluidine Blue at pH4, cartilage ECM is stained purple, and other tissue elements are 
blue. Brightfield images were taken using the same settings on an Olympus BX61 microscope. 
The total area of the explant (blue) and differentiated area (purple) were selected using the 
"magic wand" tool of the Cell Sense software (Olympus) (fig. S13). The % differentiated area 
was calculated by:  Differentiated area ÷ total area x 100 
For each implant, 2-3 sections were analysed and the one with the largest total area was 




Supplementary Figures and Tables 
 
Fig. S1. Relationship between ROR2, WNT5A, YAP, CTGF and SOX9 in in human 
osteoarthritic cartilage and healthy normal cartilage (29). n=12. (A) Biplot of principal 
component (PC) analysis. Var, variance. (B) Variance contributed by each PC. (C) Contribution 
of ROR2, WNT5A, CTGF, YAP and SOX9 to each PC and importance of each PC. (D) 
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Correlation between YAP and WNT5A, Pearson test for correlation and a linear regression 
shown by red line. Grey area indicates 95% confidence, r2 = 0.39, P = 0.00068; CTGF and 








Fig. S2. ROR2 immunostaining in murine femoral head cartilage at 0, 1 and 7 days after 
explantation (columns 2-4). Non-immune IgG (isotype) control in column 1. n= 7 (0 days), 4 (1 
day) and 3 (7 days). (A) superimposed images with ROR2 (red) and dapi (blue), bars, 20 μm. (B) 
Isolated red layer (ROR2) used for quantification. (C) isolated DAPI layer. (D) is higher 




Fig. S3. ROR2/WNT5A expression correlates with chondrocytic differentiation 
ROR2 expression in human articular chondrocytes (HAC) between passage 0 and passage 8 as 
assessed by (A) RT-PCR, n=2-3 patients, 3 technical replicates per patient. Pearson test for 
correlation and a linear regression shown by red line. Grey area indicates 95% confidence, r2 = 
0.76, P = 0.0029 and (B) by microarray (GEO Accession GSE42235), n=4, r2 = 0.59, P = 
0.00048. (C) ROR2 and WNT5A expression in synovial membrane mesenchymal stem cells 
(MSCs) differentiated with 10 ng/mL TGF-β for 6 days in micromass culture. ROR2 and WNT5A 
expression are presented relative to expression in passage 0 human articular chondrocytes (p0 





Fig. S4. ROR2 overexpression and silencing efficacy of ROR2 siRNA and shRNA  
(A) immunofluorescence staining of ROR2 (green) or FLAG (red) in C3H10T1/2 cells 
transfected with empty vector or ROR2, 24 hours after transfection. IgG, non-immune isotype 
control, dapi (blue), bars, 100 μm. (B) Western blot showing ROR2-silencing efficiency of 
ROR2 siRNA in C3H10T½ cells, with scrambled siRNA as control. n=1. (C) Western blot 
showing ROR2-silencing efficiency of lentiviral ROR2 shRNA in C3H10T½ cells, non-targeting 




Fig. S5. Silencing efficiency of atelocollagen conjugated ROR2 siRNA in vivo. Western 





Fig. S6. Treatment with ROR2i in the MLI model of osteoarthritis in mice (A) Bone volume 
fraction (BV/TV) of medial tibial subchondral plate was measured by μCT. (B) 
Histomorphometrical measurement of medial tibial subchondral bone thickness, (C) synovial 
lining thickness, (D) osteophyte perimeter and (E) osteophyte area. Representative images of 
osteophytes are shown below (D). n= 2-10, box and whiskers plots show all values, line at the 




Fig. S7. Four weeks of treatment with ROR2i in the MLI model of osteoarthritis in mice 
(A) Experimental scheme. Four weeks after menisco-ligament injury (MLI) surgery or sham 
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surgery to the contralateral leg, mice received bilateral intra-articular injections of ROR2i or 
control siRNA for four weeks, n = 5 (control), 6 (ROR2i). (B) Incapacitance was measured 
throughout the study. Circles show mean, error bars show 95% confidence intervals. Mixed 
effect linear model with pairwise comparisons at the different time points (Tukey correction of 
P-values for multiple comparisons), ** P = 0.0053, * P = 0.011. (C)  The area under the curve of 
incapacitance was calculated starting from day 26. ANOVA with Tukey’s HSD post-hoc test, P 
= 0.0047. Box and whiskers plots show all values, line at the median, boxes extend from the 25th 
to 75th percentiles, error bars span max to min values. (D) Representative images of Safranin O 
staining of the medial compartment; F, Femur; M, Meniscus; T, Tibia; bars, 200 µm. (E) 
Osteoarthritis severity was assessed using the OARSI scoring system. Box and whiskers plots 
show all values, line at the median, boxes extend from the 25th to 75th percentiles, error bars span 
max to min values. (F) histomorphometrical analysis of structural integrity and proteoglycan 
content of the articular cartilage. Two-way ANOVA with Bonferroni’s multiple comparison test, 
# P = 0.021, * P = 0.011. (G) Bone volume fraction (BV/TV) of medial tibial subchondral plate 
was measured by μCT. (H) Histomorphometrical measurement of medial tibial subchondral bone 
thickness, (I) osteophyte perimeter and (J) osteophyte area. (F-J) line at mean, standard error of 
the mean. (K) Weight gain of mice over 4 weeks of treatment with ROR2i, error bars show 











Fig. S8. ROR2 mRNA expression in HEK293 and C3H10T½ cell lines. ROR2 expression 
was normalised for β-actin, n=3, line at mean, standard error of the mean, unpaired t-test, P 































Fig. S9. WNT5A/ROR2 signaling induces nuclear accumulation of YAP in a G-protein and 
Rho dependent manner. (A) Immunostaining for YAP (red) in C3H10T½ cells: remaining 
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conditions from Fig. 6E-F. IgG, non-immune isotype control, dapi (blue), bars, 50 µm. LPA, 
lysophosphatidic acid. (B) Immunostaining for YAP (red) in C28I/2 cells: remaining conditions 
from Fig. 6G-I. IgG, non-immune isotype control, dapi (blue), bars, 50 µm. Inset shows WNT5A 
YAP staining amplified to visualise cytoplasmic staining (not used for quantification of 
intensity). (C) Quantification of the proportion of cells with prevalently nuclear, diffuse or 
cytoplasmic YAP staining: remaining conditions from Figure 6H. (D) Intensity of YAP staining 
within the nucleus: remaining conditions from Figure 6I. Box and whiskers plots show all values, 









Fig. S10.  ROR2 blockade supports cartilage homeostasis by suppressing YAP signaling. 
(A) In adulthood, under physiological conditions, ROR2 and WNT5A are expressed in low 
amounts in the cartilage. (B) Upon cartilage injury, ROR2 and WNTs (including WNT5A) are 
upregulated. WNT5A activates ROR2 signaling, which, through the co-operation of G-protein 
coupled receptors (GPCR) and Rho, induce nuclear localization of YAP and activate catabolic 
signaling. (C) Blocking ROR2 prevents nuclear localization of YAP and restores homeostasis 
through downregulation of catabolic enzymes and increased proteoglycan production. In the 
menisco-ligament injury model of osteoarthritis, this ameliorates pain and reduces structural 







Fig. S11. Mouse skin scoring system; 0=normal, 2= Mild erythema and skin induration, 





Fig. S12. Histomorphometrical analysis of joint tissues 
(A) Each image was opened in ImageJ after setting a global scale and (B) rotated so that a line 
drawn along the cartilage‐bone junction in the middle of the plateau is perfectly horizontal. (C) 
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Tibial plateau was selected using a polygon or free‐hand tool, (D) all sections were placed on a 
single large canvas. (E) Saturation stack was used to isolate the metachromatic Safranin O 
staining and a rectangle 600 microns wide and the full height of the canvas was set as the region 
of interest. (F) Density profile of each section, (G) limited the articular cartilage peak. (H) Five 
measurements of the subchondral bone were taken, perpendicular to the cartilage-bone junction 
to the top of bone marrow, or if there was no bone marrow, to the growth plate, (I) analyse > 
measure returned the length of the lines. (J) synovial thickness was measured by drawing a line 
that went horizontally through the synovial lining. Inset shows magnification, blue arrow 
indicates where the measurement was taken. (K) Medial tibial osteophytes were selected with the 




Fig. S13. Toluidine Blue quantification (A) Total area of the explant and differentiated area 
were selected using the "magic wand" tool of the Cell Sense software (Olympus). (B) Area 





Table S1 Mouse serum analysis following 10 weeks of treatment with control siRNA or 
ROR2i 
 Units Scrambled siRNA ±SD ROR2 siRNA ±SD 
ALP (U/l) 62 ±8.56 60.8 ±5.64 
ALT (U/l) 60.2 ±58.11 112 ±133.38 
AST (U/l) 157.2 ±40.03 211 ±73.51 
AST/ALT  4.053 ±1.84 3.800 ±2.16 
Total Protein (g/l) 58.98 ±3.12 58.86 ±1.52 
Albumin (g/l) 30.48 ±1.39 31.28 ±1.14 
Total Cholesterol (mmol/l) 3.838 ±0.31 4.03 ±0.28 
HDL (mmol/l) 2.354 ±0.16 2.5 ±0.11 
LDL (mmol/l) 0.744 ±0.07 0.886 ±0.12 
Glucose (mmol/l) 15.306 ±2.34 15.7 ±1.66 
Triglycerides (mmol/l) 1.434 ±0.15 1.898 ±0.43 
Total Billirubin (µmol/l) 4.76 ±0.70 4.02 ±0.23 
LDH (U/l) 2109.4 ± 617.13 1987.8 ±892.38 
Amylase (U/l) 659.4 ± 57.06 1303.4 ±1257.10 
CK (U/l) 469.8 ±126.75 731 ±220.08 
Urea (mmol/l) 8.02 ±1.02 9.48 ±1.14 
Creatinine (µmol/l) 10.30 ±0.58 11.08 ±1.49 








1 Mild erythema or skin induration 
2 Mild erythema and skin induration 
3 Eczema 
4 Severe eczema 




Table S3 Real-time PCR primer sequences 
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